FDA Approves Eli Lilly Weight-Loss Pill
Analysis based on 7 articles · First reported Apr 01, 2026 · Last updated Apr 02, 2026
The approval of Eli Lilly and Company's new weight-loss pill, orforglipron, is expected to intensify competition in the obesity treatment market, potentially impacting the market share of competitors like Novo Nordisk. Eli Lilly and Company's stock price saw a significant increase following the announcement, reflecting positive investor sentiment.
The United States — Food and Drug Administration has granted expedited approval to Eli Lilly and Company's new weight-loss pill, orforglipron, branded as Foundayo. This oral GLP-1 drug is the second daily oral medication for obesity, joining Novo Nordisk's Wegovy pill. Clinical trials showed participants on orforglipron lost an average of 11.2% of their body weight over 16 months, with improvements in various health markers. The drug is expected to ship on Monday, with prices ranging from $149 to $349 per month for cash payers, and potentially $25 with a Lilly discount card for insured individuals. Eli Lilly and Company's shares rose over 4% on the news, and the pill will be included in a Trump administration deal to lower GLP-1 drug prices.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard